Literature DB >> 2452139

Concentrations of norfloxacin in prostatic tissues following oral administration in patients with benign prostatic hyperplasia.

N R Netto1, P C Palma, G B Srulzon, P L Cortado, R C Fonseca.   

Abstract

For assessing plasma and tissue concentrations of norfloxacin after oral administration, twelve patients with benign prostatic hypertrophy (BPH) were given two doses of 400 mg norfloxacin approximately 12 hours apart prior to transurethral resection of the prostate (TURP). Prostatic tissue samples and blood samples were collected and assayed for norfloxacin content by HPLC. The mean peak norfloxacin concentration in plasma was 1.63 micrograms/ml (range 0.63 to 3.38 micrograms/ml). The mean peak concentration in prostatic tissue was 1.63 micrograms/g (range 0.75 to 3.30 micrograms/g). The plasma and prostatic tissue levels of norfloxacin exceeded the MIC's of most urinary tract pathogens. The data suggest that norfloxacin may be useful in the treatment of chronic bacterial prostatitis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452139     DOI: 10.1007/bf02583030

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Potential usefulness of norfloxacin in the treatment of urinary tract infections.

Authors:  S R Norrby
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

2.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage.

Authors:  M Eandi; I Viano; F Di Nola; L Leone; E Genazzani
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

4.  Norfloxacin versus cotrimoxazole in the treatment of lower urinary tract infections.

Authors:  H Giamarellou; J Tsagarakis; G Petrikkos; G K Daikos
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

5.  Clinical evaluation of norfloxacin versus cotrimoxazole in urinary tract infections.

Authors:  J G Guerra; E Falconi; J C Palomino; L Benavente; E Antunez de Mayolo
Journal:  Eur J Clin Microbiol       Date:  1983-06       Impact factor: 3.267

6.  In vitro antibacterial activity of norfloxacin (MK-0366).

Authors:  A King; C Warren; K Shannon; I Phillips
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

7.  Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.

Authors:  M Y Khan; R P Gruninger; S M Nelson; R E Klicker
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

  7 in total
  1 in total

1.  The effect of induced fever on the biokinetics of norfloxacin and its interaction with probenecid in goats.

Authors:  K Jha; B K Roy; R C Singh
Journal:  Vet Res Commun       Date:  1996       Impact factor: 2.459

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.